The study "GALAXY33" is an open-label, prospective, nonrandomized, one arm phase I clinical trial in which patients with relapsed AML after allogeneic hematopoietic stem cell transplantation will be transplanted with CD33-deleted CD34+ HSC derived from the initially matched family donor.
confirmed AML according to the WHO classification
relapsed disease after allo-SCT from an HLA-identical family donor (≥ 2 months after allo-SCT at time of inclusion)
≤ 29% of bone marrow blasts as detected by cytomorphology or immunohistochemistry
age ≥ 18 years
ECOG performance status >2
Confirmed CNS involvement
Acute or chronic Graft versus Host disease (GvHD)
Availability of other curative standard treatment options
German Cancer Research Center
Lead sponsor
University Hospital Heidelberg
Collaborator
University Hospital Dresden
Collaborator